In San Francisco’s jails, no inmates with hepatitis C are receiving
Sovaldi, the breakthrough pill that can cure most patients in an
unprecedented amount of time.
In California’s prisons, the drug,
made by Gilead Sciences of Foster City, is being given to less than 1
percent of the 17,000 inmates with the virus.
A Stanford University-led
study published Tuesday argues that Sovaldi, which hit the market in
December 2013, is the most cost-effective therapy for inmates because it
can deliver significant health benefits in the long run.
Labels: California, price, Sovaldi, treatment in prisons